radioimmunotherapy rit combines advantages targeted radiation therapy specific immunotherapy using monoclonal antibodies rit used target tumor cells specifically suppress immunocompetent host cells setting allogeneic transplantation choice radionuclide used rit depends distinct radiation characteristics type malignancy cells targeted lower energy longer path length suitable target bulky solid tumors high linear energy transfer short path length better suited target hematopoietic cells normal malignant different approaches rit use stable radioimmunoconjugates pretargeting strategies available encouraging results obtained rit patients hematologic malignancies results solid tumors somewhat favorable new strategies patients minimal residual disease using adjuvant locoregional treatment evolving report outlines basic principles rit gives overview available radionuclides radioimmunoconjugates discusses clinical results special emphasis use hematologic malignancies including use conditioning regimens bone marrow transplantation references NUMBER beta emitters alpha emitters